innVitro GmbH is a biotech company specialized in the measurement of cellular contractile forces in vitro, especially of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Recently, innoVitro has launched the FLEXcyte 96 platform in cooperation with Nanion Technologies, enabling the quantification of cardiac contractility under physiological mechanical conditions in 96 wells in parallel. The technology was validated with a broad range of commercially available human iPSC-derived cardiomyocytes, deliberately chosen as the most predictive and relevant cellular model available.
innoVitro offers screening services for both safety pharmacology and efficay screening.
